top
Please input keywords
OK
News events
Contact us
EN
CN
JP
KR
About us
Introduction
History
Management team
Culture
Social Responsibility
Join us
Collaborations
Antibody Assets
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
Animal Models
Humanized animal models
KO mouse models
Tool mice
Immunodeficient mice/rats
Cell lines
Aged mice
Disease mouse models
Pharmacology Service
Therapeutic area
Types of services
Molecule type
Technology
Gene Editing
By species
By technologies
By strategies
Animal Breeding
Animal Cryopreservation
Animal Rederivation
Other Services
Microbial detection
Animal Breeding
Animal Cryopreservation
Animal Rederivation
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
News events
Downloads
Poster Downloads
Media Center
News
Events
Webinar
Publication
Downloads
Poster Downloads
Brochure
2023
ESMO2023: Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with Toripalimab in patients (pts) with advanced solid tumours
2023
AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
2023
AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
2023
AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
2023
AACR 2023: Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer
2023
AACR 2023: RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
2023
AACR 2023: Discovery of RenNano®-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier
2023
AACR 2023: Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived From HLA Transgenic RenMice
2023
AACR 2023: The RenMice HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets
1
…
4
5
6
7
8
…
15
GO
